Home MarketAlembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd. Stock Info: As on 2018-05-24 15:41:22

Nse

420.70

-1.60(-0.38%)
Change%
52 Week Range
418.50
23.00
608.00
23.00
Open416.20
Day's Range337.84 - 506.76
Value Traded (in ₹ Cr.) 1.60

Bse

423.00

4.55(1.09%)
Change %
52 Week Range
418.00
23.00
596.95
23.00
Open414.00
Day's Range334.76 - 502.14
Value Traded (in ₹ Cr.) 0.12

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 137,478,753.00 72.93%
Mutual Funds/UTI 9,086,820.00 4.82%
FII 17,269,110.00 9.16%
Employee 0.00 0.00%
Public 19,911,572.00 10.56%
Government 0.00 0.00%
Others 4,126,132.00 2.19%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 3.94
Basic EPS (Rs.) 22.84
Cash EPS 27.24
BVPerShare Excl 99.06
Operating Revenue 158.40
PBDITPerShare 33.73
Dividend 4.00
NPPerShare 22.84
Current Ratio 2.32
Quick Ratio 1.23
PriceToBV 6.30
Earnings 0.03
PBDIT Margin 21.29
PBT Margin 18.41
NP Margin 14.42
Return On Assets 17.17
Retention Ratios 82.48
Parameter Mar-17 (₹ Cr.) Yoy%change
Total Income 2,988.32
Total Expenses 2,438.59
EBITDA 635.72
PBT 549.73
PAT 430.63
Net Income 430.63
More
Parameter Mar-18 (₹ Cr.) 6M % change
Total Income 1,593.73
Total Expenses 1,280.17
EBITDA 259.26
PBT 312.28
PAT 249.23
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-17 (₹ Cr.) Yoy%change
Total share capital 37.70
Net worth 1,867.32
Investments 103.04
Total Liability 2,507.78
Total debt 0.00
Net block 1,146.76
Total Assets 2,507.78
Parameter Mar-17 (₹ Cr.) 6M % change
Total share capital 37.70
Net worth 1,530.28
Investments 37.46
Total Liability 2,189.11
Total debt 0.00
Net block 789.59
Total Assets 2,189.11
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

533.05 531.95 0.21
524.95580

Abbott India Ltd.

6671.7 6587.45 1.28
65106890

Ajanta Pharma Ltd.

977.6 987 -0.95
962.351074.5

Albert David Ltd.

362.35 362.75 -0.11
356.2383.15

Alembic Ltd.

48.85 50.8 -3.84
50.254

Alkem Laboratories Ltd.

1957.55 1965.35 -0.4
18882036.65

Alpa Laboratories Ltd.

32.1 32.55 -1.38
31.5534.4
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

47.5 49.05 -3.16
46.351.55

Aarti Drugs Ltd.

530 529.15 0.16
526585

Aayush Food & Herbs Ltd.

47.7 48.1 -0.83
4355

Abbott India Ltd.

6699.95 6593.7 1.61
6465.056872.5

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-17(in ₹ Cr.)
Cash from operating activities 320.61
Cash from investing activities -504.54
Cash from financing activities -95.95
Net change in cash -279.88

Stock Held By Mutual Fund Schemes

M Venkatesh appointed MRPL MD

M Venkatesh has been appointed as the Managing Director of Mangalore Refineries and Petrochemicals Limited (MRPL), an order issued by the Personnel Ministry said today. Vekatesh is at present Director (Refineries) in the MRPL, a subsidiary of the Oil and Natural Gas Corporation Limited (ONGC) He has been appointed to the post for a period of five years with effect from the date of his assumption of charge of the post on or after June 1, 2018, or till the date of his superannuation, the order said.

24-05-2018 11:42

TCS expands operations in Florida as part of Transamerica deal

India's largest IT services firm TCS today said it has expanded operations in Florida, US, with over 430 employees joining the company as part of its deal with Transamerica. In January, Tata Consultancy Services (TCS) had signed an over USD 2 billion deal with Transamerica to administer the latter's life insurance, annuity, supplemental health insurance, and workplace voluntary benefits products. It covered managing administration of more than 10 million policies. More than 430 former Transamerica employees now work for TCS at this new St Petersburg facility (in Florida) as part of recruiting and investing in more than 2,200 Transamerica jobs across the US in multiple locations, the Indian software services giant said in a statement. TCS will occupy several floors of Transamerica's building at 570 Carillon Parkway in St Petersburg, as part of a multi-year agreement with Transamerica... The St Petersburg office is a new US business centre for TCS, adding to the over 1,000 employees already serving American businesses throughout the state, it added. TCS said it has invested nearly USD 3 billion in the US over the past three years and has been among the top two IT services job creators in the country. TCS is a leading industry employer in the US, striving to help American companies like Transamerica to digitally transform their business and capitalise on rapidly evolving customer demands, TCS President and Global Head (Banking, Financial Services and Insurance Platforms) Suresh Muthuswami said. We look forward to partnering with St Petersburg's city, state and local organizations to further build upon our business and community impact, he added. The company said it has made tremendous community impact in Florida over past several years.

24-05-2018 11:16

Kotak India Growth Fund Series 4 - Direct Plan: change in investment factsheets for April

Kotak India Growth Fund Series 4 - Direct Plan has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.89 for Growth, while 52-Week High and Low ranges were Rs 10.35 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 - Direct Plan is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

Kotak India Growth Fund Series 4: change in investment factsheets for April

Kotak India Growth Fund Series 4 has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.88 for Growth, while 52-Week High and Low ranges were Rs 10.34 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

BLS International to assist Sopra Steria on UK visa renewals

Visa service provider BLS International today said theUnited Kingdom Visas and Immigration (UKVI) has awarded Sopra Steria a new contract to enable visa renewals for those individuals who are already in the UK. BLS International will support Sopra Steria and UKVI, a division of the UK Home Office responsible for deciding who can visit and stay within the UK, by establishing and delivering some of the key add value services under the contract, it said in a release. BLS International claims to handle about 12 million visa applications annually across the globe at present. Meanwhile, shares of the company were trading at Rs 172.55 apiece, up 1 per cent from the previous close at 10:50 hours on BSE.

24-05-2018 10:51

Alembic Pharmaceutic - Disclosure under SEBI Takeover Regulations

Laksh Trust has submitted to the Exchange, vide letter dated May 23, 2018 a copy of disclosure under Regulation 10(5) in respect of acquisition under Regulation 10 of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

23-May-2018 07:46 PM

Alembic Pharmaceutic - Updates

Alembic Pharmaceuticals Limited has informed the Exchange regarding ''US FDA Inspection at Alembic Pharmaceuticals API Facility at Karkhadi''.

18-May-2018 03:53 PM

Alembic Pharmaceutic - US FDA Inspection At Alembic Pharmaceuticals API Facility At Karkhadi.

We would like to inform that the United States Food and Drug Administration (US FDA) has conducted an inspection at Alembic Pharmaceuticals API Facility located at Karkhadi from 14th May, 2018 to 18th May, 2018. This was a scheduled inspection and at the end of the inspection, the US FDA issued a Form 483 with one observation.

The Company is preparing the response to the observation, which will be submitted to the US FDA shortly.

We request you to kindly take the same on record.

18-May-2018 03:22 PM

Alembic Pharmaceutic Q4 net profit zooms 143.40% at Rs 144.19 cr

The company reported standalone net profit of Rs 144.19 crore for the quarter ended March 31, 2018 as compared to Rs 59.24 crore in the same period last year, registering a year-on-year growth of 143.40 per cent. Net revenue of the company rose substantially by 30.41 per cent at Rs 838.22 crore in January-March quarter of this fiscal as against Rs 642.75 crore in the corresponding period last year. During January-March quarter, operating expenses increased by 15.88 per cent to Rs 631.43 crore from Rs 544.92 crore in year ago period. Other Income dipped by 68.54 per cent at Rs 0.28 crore versus (Mar'17 Rs 0.89 crore). Operating Profit surged by 109.81 per cent to Rs 206.79 crore as against Rs 98.56 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 60.93 per cent in March quarter. Interest declined by 50.77 per cent y-o-y to Rs 0.64 crore, while Taxation increased by 100.94 per cent at Rs 34.32 crore (Mar'17 Rs 17.08 crore).

17-May-2018 05:15 PM

Alembic Pharmaceutic - Audited Financial Results Of The Company For The Financial Year Ended 31St March, 2018.

Approved the Audited Financial Results of the Company for the financial year ended 31st March, 2018.

16-May-2018 09:47 PM

Alembic Pharmaceutic - US FDA Inspection At Alembic Pharmaceuticals API Facility At Karkhadi.

We would like to inform that the United States Food and Drug Administration (US FDA) has conducted an inspection at Alembic Pharmaceuticals API Facility located at Karkhadi from 14th May, 2018 to 18th May, 2018. This was a scheduled inspection and at the end of the inspection, the US FDA issued a Form 483 with one observation.

The Company is preparing the response to the observation, which will be submitted to the US FDA shortly.

We request you to kindly take the same on record.

18-May-2018 03:22 PM

Alembic Pharmaceutic - Audited Financial Results Of The Company For The Financial Year Ended 31St March, 2018.

Approved the Audited Financial Results of the Company for the financial year ended 31st March, 2018.

16-May-2018 09:47 PM

Alembic Pharmaceutic - Corporate Action-Board approves Dividend

Recommended a dividend of Rs. 4.00 (200%) per Equity Share having face value of Rs. 2/- each, subject to approval of the Shareholders at the ensuing Annual General Meeting.

16-May-2018 02:51 PM

Corporate Details

About Management

2011 Alembic Pharmaceuticals Limited ( the Resulting C ompany ) was originally incorporated on 16th June, 2010 in the name and style 'Alembic Pharma Limited', under the Companies Act, 1956 and had received the Certificate of Commencement of business on 1st July, 2010. The company changed its name from Alembic Pharma Limited to Alembic Pharmaceuticals Limited and the Registrar of Companies, Gujarat has approved the change of name and issued a fresh certificate of incorporation consequent upon change of name on 12th March, 2011. 2012 Alembic and Breckenridge Announce Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiqr). Alembic Pharmaceuticals Limited enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. 2013 -Alembic gets USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA. 2014 -"Alembic announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.". 2015 -Alembic Pharmaceuticals Ltd. arm signs exclusive agreement with Novartis 2016 - Alembic Pharma inks JV agreement with Orbicular Pharma 2017 -Alembic Pharmaceuticals partners with Breckenridge Pharma launching tablets used in the treatment of major depressive disorder. -Alembic Pharma gets USFDA nod for generic antidepressant and anti-hypertension drugs. -Alembic gets FDA tentative nod for erectile dysfunction drug. -Alembic Pharma gets USFDA nod for anti-bacterial drug. -Alembic Pharma completes acquisition of Orit Laboratories.

Registered Office

Samardung Busty, Namthang,

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.